Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 5, 2013, Pages 303-311

  Wei, Hongyan ^a   Song, Juan ^a   Li, Hao ^b   Li, Yang ^b   Zhu, Shanshan ^a   Zhou, Xiaodan ^a   Zhang, Xiwen ^a   Yang, Li ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Shenyang Shuangding Pharmaceutical Co Ltd   (China)

Author keywords

Cytotoxicity; Irinotecan hydrochloride; Liposomes; Pharmacokinetics; Transmembrane ammonium salts gradient

Indexed keywords

EID: 84922779125     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.10.006     Document Type: Article

References (35)

1. Yoshimatsu, K., Kato, H., Ishibashi, K., et al. Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother Pharmacol 52 (2003), 465–468.
2. Goldberg, M.G., Gill, S., Recent phase III trials of fluorouracil, irinotecan and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 54 (2004), 57–64.
3. Sugiyama, T., Yakushiji, M., Nishida, T., et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128 (1998), 211–218.
4. Ohyanagi, F., Horiike, A., Okano, Y., et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol 61 (2008), 503–508.
5. Negoro, S., Masuda, N., Takada, Y., et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced nonsmall cell lung cancer. Br J Cancer 88 (2003), 335–341.
6. Sone, M., Uchida, I., Tominaga, M., et al. Small cell carcinoma of the larynx treated with irinotecan and cisplatin. Auris Nasus Larynx 33 (2006), 223–225.
7. Muhr-Wilkenshoff, F., Hinkelbein, W., Ohnesorge, I., et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 18 (2003), 330–334.
8. Takahashi, Y., Kitakata, H., Yamashita, K., et al. Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer. Surg Today 34 (2004), 246–250.
9. Fadul, C.E., Kingman, L.S., Meyer, L.P., et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 90 (2008), 229–235.
10. Ohno, R., Okada, K., Masaoka, T., et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8 (1990), 1907–1912.
11. Bleiberg, H., Cvitkovic, E., Characterization and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 32 (1996), 18–23.
12. Cersosimo, R.J., Irinotecan a new antineoplastic agent for the management of colorectal cancer. J Ann Pharmacother 32 (1998), 1324–1333.
13. Yoshiyuki, H., Li, S., Wu, X.D., Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release 136 (2009), 30–37.
14. Sadzuka, Y., Hirotsu, S., Hirota, S., Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett, 127, 1998 99–106.
15. Sadznka, Y., Hirotsn, S., Hirota, S., Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 90 (1999), 226–232.
16. Ramsay, E., Alnajim, J., Anantha, M., Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res 23 (2006), 2799–2808.
17. Dicko, A., Tardi, P., Xie, X., et al. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm 337 (2007), 219–228.
18. Walsh, F.M., Crosson, F.J., Bayley, M., et al. Acute copper intoxication pathophysiology and therapy with a case report. Am J Dis Child 131 (1977), 149–151.
19. Barceloux, D.G., Copper. J Toxicol Clin Toxicol 37 (1999), 217–230.
20. Kawanishi, S., Inoue, S., Yamamoto, K., et al. Hydroxyl radical and singlet oxygen production and DNA damage induced by carcinogenic metal compounds and hydrogen peroxide. Biol Trace Elem Res 21 (1989), 367–372.
21. Sumiyoshi, H., Fujiwara, Y., Ohune, T., et al. High-performace liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B 670 (1995), 309–316.
22. Fan, M., Xu, S., Xia, S., et al. Preparation of salidroside nano-liposomes by ethanol injection method and in vitro release study. Eur Food Res Technol 227 (2008), 167–174.
23. Smith, R.N., Hansch, C., Ames, M.M., Selection of a reference partitioning system for drug design work. J Pharm Sci 64 (1975), 599–606.
24. Barenholz, Y., Liposome application: problems and prospects. Colloid Interface Sci 6 (2001), 66–77.
25. Gabizon A, Barenholz Y. Method for drug loading in liposomes. U.S Patent 988275/10 2005.
26. Wasserman, V., Development, characterization, optimization, and pharmacokinetic evaluation of liposome-based piperidine nitroxide formulation for treatment of pathological conditions: tumor and rheumatoid arthritis. Ph.D. thesis, 2002.
27. Haran, G., Cohen, R., Bar, L.K., et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151 (1993), 201–215.
28. Dicko, A., Tardi, P., Xie, X.W., et al. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm 337 (2007), 219–228.
29. Bolotin, E.M., Cohen, R., Bar, L.K., Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes. J Liposome Res 4 (1994), 455–479.
30. Chou, T.H., Chen, S.C., Chu, I.M., et al. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng 95 (2003), 405–408.
31. Ramsay, E., Alnajim, J., Anantha, M., et al. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm 68 (2008), 607–617.
32. Lasic, D.D., Frederik, P.M., Stuart, M.C.A., et al. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett 312 (1992), 255–258.
33. 14C] phosphatidylcholine between liposomes and human plasma high density lipoprotein. Biochim Biophys Acta 712 (1982), 444–452.
34. Sadzuka, Y., Hirotsu, S., Hirota, S., Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 90 (1999), 226–232.
35. Hennebelle, I., Terret, C., Chatelut, E., et al. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Anti-Cancer Drugs 6 (2000), 465–470.